Roche Launches New Phase 3 Trial of Elevidys for European Approval
Roche announces a new Phase 3 clinical trial of Elevidys, a controversial gene therapy for Duchenne muscular dystrophy, following European regulators' rejection of the treatment last year due to insufficient evidence of long-term patient benefits. The 72-week trial will enroll approximately 100 boys in early disease stages and evaluate Elevidys against placebo, generating evidence for potential resubmission to European officials and regulatory agencies worldwide. Roche holds rights to Elevidys outside the United States, while developer Sarepta Therapeutics markets the therapy domestically. The trial represents a critical effort to secure European approval for a treatment that has become controversial despite its U.S. availability.
Roche's New Phase 3 Trial for European Approval
▪Roche has rights to Elevidys outside the United States.
▪Roche announced on Thursday it would run another trial of the Duchenne muscular dystrophy gene therapy Elevidys.
▪Roche's Phase 3 trial of Elevidys will generate evidence for applications with regulatory agencies in other parts of the world.
▪Elevidys is marketed in the United States by its developer, Sarepta Therapeutics.
▪Roche's Phase 3 trial of Elevidys will generate evidence that could lead to a resubmission with European officials.
European Regulatory Rejection and Controversy
▪Elevidys has become a controversial medicine.
▪European regulators gave a negative review to Elevidys last year.
▪European regulators said Elevidys had failed to demonstrate long-term benefits for patients with Duchenne muscular dystrophy.
Trial Design and Patient Population
▪Roche's Phase 3 trial of Elevidys will enroll roughly 100 boys at the early stages of Duchenne muscular dystrophy.
▪Roche's Phase 3 trial of Elevidys will evaluate the safety and efficacy of Elevidys versus placebo over 72 weeks.
Perspective of European regulators
▪European regulators require demonstration of long-term benefits before approving Duchenne muscular dystrophy treatments.
▪The evidence submitted for Elevidys to European regulators was insufficient to support approval.
Perspective of Sarepta Therapeutics
▪Sarepta Therapeutics developed Elevidys as a gene therapy for Duchenne muscular dystrophy.
▪Sarepta Therapeutics retained marketing rights for Elevidys in the United States while licensing international rights to Roche.
Perspective of Duchenne muscular dystrophy patient community
▪European patients with Duchenne muscular dystrophy currently lack access to Elevidys due to the regulatory rejection.
Story comments
Loading comments…